Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Development of dEep EndometrioSis Following Acute haemoPerITonEum (DEESPITE)

This study investigates whether acute pelvic pain with haemoperitoneum is associated with an increased risk of developing deep pelvic endometriosis, compared with acute pelvic pain without haemoperitoneum. Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to a single follow-up visit, including a transvaginal ultrasound and validated questionnaires.

Panoramica dello studio

Stato

Reclutamento

Descrizione dettagliata

This is a single-centre, non-pharmacological, interventional, no-profit study conducted at the Obstetric-Gynecological Emergency Department and the Infertility Unit of Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.

Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024 will be invited to participate. Cases are women with documented haemoperitoneum and no previous diagnosis of endometriosis. Controls are women with acute pelvic pain without haemoperitoneum and no previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year). Women with previous hysterectomy or oophorectomy, or established menopause, are excluded.

Participants who provide informed consent will attend a single follow-up visit, lasting approximately one hour. The visit includes a second-level transvaginal ultrasound to identify lesions suggestive of deep endometriosis according to the IDEA criteria, and validated questionnaires assessing quality of life (SF-12), endometriosis-specific quality of life (EHP-30), sexual function (FSFI) and pain (NRS).

The primary outcome is the incidence of sonographically diagnosed deep pelvic endometriosis between 6 months and up to 5 years after the acute event, comparing cases and controls. Secondary outcomes include the impact of the acute event on chronic pelvic pain and quality of life, and the association between treatment of the acute event (surgical vs conservative) or use of hormonal therapy during follow-up and the development of endometriosis.

Tipo di studio

Osservativo

Iscrizione (Stimato)

32

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 50 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Women aged 18-50 who attended the Obstetric-Gynecological Emergency Department for acute pelvic pain between January 2020 and December 2024

Descrizione

Inclusion Criteria:

  • Women aged 18-50 years
  • Female sex
  • Attendance at the Obstetric-Gynecological Emergency Department (Clinica Mangiagalli) for acute pelvic pain
  • For cases: documented haemoperitoneum without a previous diagnosis of endometriosis
  • For controls: no documented haemoperitoneum without a previous diagnosis of endometriosis

Exclusion Criteria:

  • Previous hysterectomy and/or oophorectomy
  • Established menopause

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: CASE_CONTROL
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Haemoperitoneum

Women aged 18-50 with acute pelvic pain and documented haemoperitoneum, without a previous diagnosis of endometriosis

No haemoperitoneum

Women aged 18-50 with acute pelvic pain and no documented haemoperitoneum, without a previous diagnosis of endometriosis, matched to cases by age (±2 years) and year of the event (±1 year)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of sonographically diagnosed deep pelvic endometriosis
Lasso di tempo: From 6 months up to 5 years after the acute event

Incidence of deep pelvic endometriosis diagnosed by second-level transvaginal ultrasound according to IDEA criteria, comparing cases (haemoperitoneum) and controls (no haemoperitoneum)

From 6 months up to 5 years after the acute event

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pelvic pain intensity assessed using the Numeric Rating Scale (NRS)
Lasso di tempo: From 6 months up to 5 years after the acute event

Comparison of pelvic pain intensity between participants with and without haemoperitoneum at the index acute event, assessed using the Numeric Rating Scale (NRS). Scores range from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.

From 6 months up to 5 years after the acute event
Endometriosis-related quality of life assessed using the Endometriosis Health Profile-30 (EHP-30)
Lasso di tempo: From 6 months up to 5 years after the acute event

Comparison of the Endometriosis Health Profile-30 (EHP-30) overall summary score between participants with and without haemoperitoneum at the index acute event. The core questionnaire contains 30 items, each scored from 0 to 4. A single overall score is calculated by summing the scores of all 30 items, dividing the sum by the maximum possible score of 120, and multiplying by 100. The overall score ranges from 0 to 100, with higher scores indicating worse health-related quality of life.

From 6 months up to 5 years after the acute event
Quality of life assessed using the Short Form Health Survey (SF-12)
Lasso di tempo: From 6 months up to 5 years after the acute event

Comparison of the 12-Item Short Form Health Survey (SF-12) scores between participants with and without haemoperitoneum at the index acute event. Scores will be calculated using the questionnaire's standard scoring algorithm. Norm-based scores have a reference population mean of 50 and a standard deviation of 10, with higher scores indicating better physical health-related quality of life.

From 6 months up to 5 years after the acute event
Sexual function assessed using the Female Sexual Function Index (FSFI)
Lasso di tempo: From 6 months up to 5 years after the acute event

Comparison of Female Sexual Function Index (FSFI) total scores between participants with and without haemoperitoneum at the index acute event. The FSFI is a 19-item questionnaire assessing six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Weighted domain scores are summed to obtain a total score ranging from 2 to 36, with higher scores indicating better sexual function.

From 6 months up to 5 years after the acute event
Odds ratio for endometriosis diagnosis according to initial treatment
Lasso di tempo: From 6 months up to 5 years after the acute event

Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants initially managed surgically with those managed conservatively. Initial treatment will be classified from medical records. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no).

From 6 months up to 5 years after the acute event
Odds ratio for endometriosis diagnosis according to hormonal therapy use
Lasso di tempo: From 6 months up to 5 years after the index acute event.

Odds ratio with 95% confidence interval for a diagnosis of endometriosis following the index acute event, comparing participants who received hormonal therapy during follow-up with those who did not. Endometriosis diagnosis will be established according to the study diagnostic criteria. The odds ratio will be estimated using logistic regression, with endometriosis diagnosis coded as a binary outcome (yes/no).

From 6 months up to 5 years after the index acute event.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 aprile 2026

Completamento primario (Stimato)

1 giugno 2027

Completamento dello studio (Stimato)

1 giugno 2027

Date di iscrizione allo studio

Primo inviato

3 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi